Personalis Free Cash Flow 2018-2024 | PSNL
Personalis free cash flow from 2018 to 2024. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
Personalis Annual Free Cash Flow |
2023 |
-67.17 |
2022 |
-120.13 |
2021 |
-81.91 |
2020 |
-45.90 |
2019 |
-26.45 |
2018 |
-2.28 |
2017 |
-4.87 |
Personalis Quarterly Free Cash Flow |
2024-09-30 |
-37.47 |
2024-06-30 |
-31.03 |
2024-03-31 |
-20.52 |
2023-12-31 |
-67.17 |
2023-09-30 |
-50.23 |
2023-06-30 |
-32.68 |
2023-03-31 |
-19.52 |
2022-12-31 |
-120.13 |
2022-09-30 |
-93.83 |
2022-06-30 |
-57.65 |
2022-03-31 |
-19.99 |
2021-12-31 |
-81.91 |
2021-09-30 |
-63.06 |
2021-06-30 |
-42.22 |
2021-03-31 |
-12.18 |
2020-12-31 |
-45.90 |
2020-09-30 |
-42.53 |
2020-06-30 |
-24.85 |
2020-03-31 |
-8.72 |
2019-12-31 |
-26.45 |
2019-09-30 |
-26.94 |
2019-06-30 |
-13.64 |
2019-03-31 |
-0.89 |
2018-12-31 |
|
2018-09-30 |
-4.81 |
2018-06-30 |
-2.44 |
2017-12-31 |
|
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical - Generic Drugs |
$0.245B |
$0.073B |
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
|